EcoDrugPlus

Tubulin Beta 1 Class Vi

Ensembl ID : ENSSFOG00015011762
Gene Symbol: TUBB1
3 Cross references
184 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSSFOG00015022788
Gene Symbol: TP53
3 Cross references
160 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSSFOG00015000107
Gene Symbol: TP53
3 Cross references
232 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSSFOG00015009207
Gene Symbol: LOC108920029
3 Cross references
140 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSSFOG00015016560
Gene Symbol: TYR
1 Cross references
202 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSSFOG00015011619
Gene Symbol: TYR
3 Cross references
198 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSSFOG00015002530
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSSFOG00015023672
Gene Symbol: TYK2
3 Cross references
196 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSSFOG00015022550
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Hck-Like

Ensembl ID : ENSSFOG00015020335
Gene Symbol: LOC108926451
2 Cross references
134 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSSFOG00015014741
Gene Symbol: LOC108937715
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo

Ensembl ID : ENSSFOG00015022775
Gene Symbol: LOC108941151
2 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).